Abstract: The application relates to a method and device for quantitatively analyzing the detection results of lateral flow-type test kits. Disclosed is a method for quantitatively analyzing the test results of a lateral flow-type test kit wherein the test kit includes a result area in which a control C-line region and a detection T-line region are set.

Abstract: In this invention, prediction on the predisposition of a human test subject to cancer is made based on machine learning-assisted comparison of the copy number variations (“CNV”) found in the constitutional DNA of the test subject with a set of diagnostic recurrent CNV features (viz. markers) selected from a collection of constitutional DNA samples from noncancer subjects (designated as “Noncancer DNA” samples) plus constitutional DNA samples from cancer patients (designated as “Cancer DNA” samples), all from the same ethnic group as the test subject. Selection and testing of the set of diagnostic recurrent CNV features is performed using a machine learning procedure, exemplified by the CFS-based method, the Frequency-based method and the Classifier-based method, together with the Naïve Bayes classification method. Prediction of the test subject's predisposition to cancer is also performed with the Naïve Bayes classification method.

Abstract: The invention provides compositions containing an effective amount of a therapeutic agent encapsulated in a liposome coupled to a desialyated glycoprotein, e.g., desialyated glycoprotein-?1. This invention further provides methods for the targeted delivery of a therapeutic agent to a tissue expressing asialoglycoprotein receptors by delivery to the tissue an effective amount of a composition containing an effective amount of the agent encapsulated in a liposome coupled to a desialyated glycoprotein, e.g., desialyated glycoprotein-?1. Also provided by this invention is a method for inhibiting the proliferation of liver cancer by administering to a subject in need of such therapy an effective amount of a composition containing doxorubicin encapsulated in desialyated glycoprotein-?1 coupled to a liposome.

Abstract: The invention provides compositions containing an effective amount of a therapeutic agent encapsulated in a liposome coupled to a desialyated glycoprotein, e.g., desialyated glycoprotein-&agr;1. This invention further provides methods for the targeted delivery of a therapeutic agent to a tissue expressing asialoglycoprotein receptors by delivery to the tissue an effective amount of a composition containing an effective amount of the agent encapsulated in a liposome coupled to a desialyated glycoprotein, e.g., desialyated glycoprotein-&agr;1. Also provided by this invention is a method for inhibiting the proliferation of liver cancer by administering to a subject in need of such therapy an effective amount of a composition containing doxorubicin encapsulated in desialyated glycoprotein-&agr;1 coupled to a liposome.